Pharmacologic treatments for covid-19 patients

Hyperimmune anti-COVID-19 Intravenous Immunoglobulin vs Standard care/Placebo


Hospitalized patients

Forest plots
(last update: 2022-10-07)

Summary of findings
(last update: 2022-10-13)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=794

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
NCT04546581
ITAC (INSIGHT 013)
Polizzotto MN, Lancet, 2022
Full text
Commentary
Commentary
Mixed

Hyperimmune anti-COVID-19 Intravenous Immunoglobulin

Placebo

RCT Patients with confirmed COVID-19 (mild-severe) admitted to 63 centers in Argentina, Denmark, Germany, Greece, Indonesia, Israel, Japan, Nigeria, Spain, UK, and USA. N=593
Some concerns
Details

Full description

CTRI/2020/09/027903
Parikh D, Indian Pract, 2021
Full text
Full text
Commentary
Commentary
Private

Hyperimmune anti-COVID-19 Intravenous Immunoglobulin

Standard care

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 7 centers in India. N=60
Some concerns
Details

Full description

NCT04521309
Ali S, EClinicalMedicine , 2021
Full text
00206-6/fulltext Commentary
Public/non profit

Hyperimmune anti-COVID-19 Intravenous Immunoglobulin

Standard care

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Pakistan N=50
Some concerns
Details

Full description